Dr. Mark′s Education went on in Boston University School of Medicine Boston Massachusetts Ph.D. in Biochemistry University of Massachusetts Amherst Massachusetts B.S in Zoology.

His Research Interest includes Ischemia or reperfusion injury, gene expression, amyloid formation and Alzheimers disease, protein structure and function.

Lotta focus in her laboratory is on neuroplasticity during development and aging especially related to neurodegenerative disease In particular we are studying factors that influence physiological function of the nervous system such as neurotrophic factors reactive oxygen species ROS and pro and antiinflammatory cytokines An important line of work in the lab is to understand biological mechanisms for cognitive impairment in Down Syndrome DS and design novel treatment paradigms for this progressive condition We have primarily focused on trophic factor influence on cholinergic adrenergic and dopaminergic pathways in the brain and the neurotrophic factors NGF and GDNF as well as oxidative stress and inflammation resulting from a lack of these factors Other ongoing studies in the laboratory are related to estrogen/testosterone replacement therapy as well as dietary supplementation with antioxidants and lowcholesterol diets The overall goal of the laboratory is to develop treatment strategies for Down syndrome Parkinsons and Alzheimers disease by using growth factors hormone replacement or dietary prevention therapies We are using a systems approach studying memory and movement behaviors and correlating these behavioral data with biochemical and structural correlates in the brain Recently we have incorporated a translational research approach with ongoing studies together with clinical laboratories around our campus and at other neuropathology centers In 2009 I initiated the Carroll A Campbell Jr Neuropathology Laboratory in collaboration with Dr Kumar Sambamurti with the help of a generous donation from Governor Campbells family This is a human brain bank with the purpose of procuring brains from healthy older adults as well as individuals with neurodegenerative disorders including AD associated with DS PD and stroke to study the specific demographics of neurodegenerative disorders in our state and surrounding areas

Lotta Research Interest is to develop treatment strategies for Down syndrome, Parkinsons and Alzheimers disease by using growth factors, hormone replacement, or dietary prevention therapies. We are using a systems approach, studying memory and movement behaviors, and correlating these behavioral data with biochemical and structural correlates in the brain.

Elan D. Louis M.D., M.Sc. received his training from the University of Pennsylvania (B.A. 1984), Yale Medical School (M.D. 1989), Columbia University School of Public Health (M.S. in Epidemiology 1995) and the New York Neurological Institute at Columbia-Presbyterian Medical Center (Neurology Residency 1990-93, Movement Disorder Fellowship 1993-95, and Neuroepidemiology Fellowship, 1993-95). Currently, he is Professor of Neurology and Epidemiology at Columbia University and Associate Chairman of Neurology. He has a focused academic interest in movement disorders and especially in tremor disorders. He currently collaborates with investigators in Spain, Turkey, China, Bangladesh and Mexico examining the epidemiology of neurological disorders in these populations. He has received continuous funding from the National Institutes of Health (NIH) since 1995 for his research on essential tremor (ET) and currently heads the Essential Tremor Centralized Brain Repository at Columbia University, which is a centralized brain bank for the study of essential tremor. He is the author of over 330 scientific papers and book chapters and currently serves on several editorial boards.

Elan focused academic interest in movement disorders and especially in tremor disorders. His research efforts have concentrated on the familial aggregation of tremor, the environmental epidemiology of tremor, the role of neurotoxins in tremor, and the pathological basis of tremor.

David education of M.D was in 1977 at Emory University, Residency, Emory University; Fellowship, Boston University, Certification, 1983, American Board of Psychiatry and Neurology; 1994, Sleep Medicine.

David research interests include Dementia/Alzheimer disease, Neurobehavioral disorders, Sleep Medicine.

Piotr Lewczuk heads the Laboratory for Clinical Neurochemistry and Neurochemical Dementia Diagnostics at the Department of Psychiatry and Psychotherapy Universitatsklinikum Erlangen. This ISO 9001:2008 certified lab is one of the European leading centers for neurochemical diagnosis of dementia NDD and one of the five worldwide reference centers together with three other European and one American laboratories in the Alzheimers Association supported project on CSF biomarkers international quality control coordinated by Prof Dr K Blennow For more than ten years. Dr. Lewczuk has been working on diagnostic and research aspects of cerebrospinal fluid analysis including a broad range of neurologic and psychiatric disorders multiple sclerosis and other neuroinflammations acute and chronic neuroinfections stroke etc with a particular focus on neurodegenerating conditions like Alzheimers disease. In 2004 he obtained the Certificate of Expertise from the German Society of Clinical Neurochemistry to become one of seventy certified clinical neurochemists in Germany and is a member of the Extended Board of this Society In the context of transnational promotion of NDD methods and protocols which is one of the longitudinal goals of his research activities. Dr Lewczuk is also a member of the Scientific Advisory Board of the Alzheimer Diagnostic and Therapy Center at the Medical University of Wroclaw Poland in Scinawa and a consultant of a worldwide leading diagnostic biotech company Innogenetics Ghent Belgium. Recently Dr Lewczuk joined the Editorial Board of the Journal of Alzheimers Disease as an Associate Editor The main topics of the current research interest include a discovery also in a close cooperation with industrial partners of novel potential biomarkers of neurodegenerative disorders and their transfer into clinical routine b optimization of the analytical performance of the existing biomarkers c application of multiplexing technologies for the biomarkers discovery and validation d search for biomarkers for differential diagnosis among different dementias e search for possible biomarkers in other body fluids blood inter and intralaboratory quality control issues with special focus on quality management  organization and management of a largescale multicenter biobanking of human body fluids.

Piotr main topics of the current research interest include a) discovery, also in a close cooperation with industrial partners, of novel potential biomarkers of neurodegenerative disorders, and their transfer into clinical routine b) optimization of the analytical performance of the existing biomarkers c) application of multiplexing technologies for the biomarkers discovery and validation d) search for biomarkers for differential diagnosis among different dementias e) search for possible biomarkers in other body fluids (blood) f) inter- and intra-laboratory quality control issues with special focus on quality management g) organization and management of a large-scale multicenter biobanking of human body fluids.

Jesús Avila is Professor and former Director of the Center of Molecular Biology Madrid Spain During the last thirty years have been working in neuron cytoskeleton. Now he studies the role of tau protein in neurodegenerative disorders tauopathies like Alzheimer disease. He is member of different Organizations like EMBO European Academy and the Spanish Royal Academy of Sciences; he is member of different Editorial Boards and has more than 300 publications most of them related with Alzheimer disease.

Jesus Research Interest includes role of tau protein in neurodegenerative disorders (tauopathies) like Alzheimer disease, neuron cytoskeleton.

George Perry is dean of the College of Sciences and professor of biology at The University of Texas at San Antonio. Perry is recognized in the field of Alzheimers disease research particularly for his work on oxidative stress.
Perry received his bachelors of arts degree in zoology with high honors from University of California, Santa Barbara.  After graduation, he headed to Scripps Institution of Oceanography and obtained his Ph.D. in marine biology under David Epel in 1979. He then received a postdoctoral fellowship in the Department of Cell Biology in the laboratories of Drs. Bill Brinkley and Joseph Bryan at Baylor College of Medicine where he laid the foundation for his observations of abnormalities in cell structures. In 1982, Perry joined the faculty of Case Western Reserve University, where he currently holds an adjunct appointment. He is distinguished as one of the top Alzheimer’s disease researchers with over 800 publications, one of the top 100 most-cited scientists in neuroscience and behavior and one of the top 25 scientists in free radical research. Perry has been cited over 23,000 times and is recognized as an ISI highly cited researcher. Perry is editor for numerous journals and is editor-in-chief for the Journal of Alzheimers Disease. He is a fellow of the American Association for the Advancement of Sciences and past-president of the American Association of Neuropathologists, as well as a member of the Dana Alliance for Brain Initiatives. Perry is recognized internationally for his work. He is a Foreign Correspondent Member of the Spanish Royal Academy of Sciences and a Foreign Member of the Mexican National Academy of Sciences, and recent recipient of the National Plaque of Honor from the Republic of Panama Ministry of Science and Technology.

Perry′s research is primarily focused on how Alzheimer disease develops and the physiological consequences of the disease at a cellular level. He is currently working to determine the sequence of events leading to damage caused by and the source of increased oxygen radicals.

Dr. Khalid Iqbal is Professor and Chairman, Department of Neurochemistry at the New York State Institute for Basic Research in Developmental Disabilities, Staten Island, New York.  He received his Ph.D. in Biochemistry in 1969 from the University of Edinburgh, Edinburgh, U.K.  His pioneering studies on neuronal protein pathology and discoveries of tau protein and its abnormal hyperphosphorylation in Alzheimer disease has won him many prestigious honors and awards, including the Potamkin Prize for Alzheimer Disease research from the American Academy of Neurology, and the Zenith Award from the Alzheimer’s Association, U.S.A.  In 2007, Alzheimer’s Association, USA, established a Khalid Iqbal Life Time Achievement Award for Alzheimer’s disease Research, which is given out annually at the International Conference on Alzheimer’s disease (ICAD) to a senior established Alzheimer disease researcher.  Dr. Iqbal has authored over 200 scientific papers in prestigious American and international scientific journals and edited seven books on research advances in Alzheimer disease and related neurodegenerative disorders. 

Khalid research interests include Alzheimer Disease, Neurology.

Dr D.P. Devanand is Professor of Clinical Psychiatry and Neurology at the College of Physicians and Surgeons Columbia University. He completed medical school at Christian Medical College Vellore in India and trained in psychiatry at the National Institute of Mental Health and Neurosciences Bangalore India. He completed psychiatry residency training at SUNY Upstate Medical Center Syracuse and Yale University School of Medicine. He then did a clinical research fellowship in Biological Psychiatry at Columbia University and has continued on the faculty at Columbia University since 1987. Currently he is CoDirector of the Memory Disorders Center and CoDirector of the Late Life Depression Clinic at the New York State Psychiatric Institute. His research studies involve Alzheimer disease geriatric depression and electroconvulsive therapy. His research has helped define the clinical features and treatment response in elderly patients with chronic mild to moderate depression or dysthymic disorder. He pioneered studies on the interface between depression and cognitive impairment in the elderly and he is also known for his research into early diagnostic markers of Alzheimer disease and the treatment of behavioral complications in Alzheimer disease. He has been principal investigator on several research grants from the National Institute of Aging and the National Institute of Mental Health He has also been funded by the Alzheimer Association NARSAD and the Dana Foundation. He has published over 180 research papers and articles and is the author of three books.

Devanands research is in to early diagnostic markers of Alzheimer disease and the treatment of behavioral complications in Alzheimer disease.

The Castellani lab is dedicated to the study of the pathology and pathogenesis of neurodegenerative diseases, with the ultimate goal of identifying and characterizing upstream biological events that may be targeted for therapy, and that are more closely aligned to etiology than current paradigms. We have particular expertise in the study of oxidative stress as applied to human brain; specifically, redox active transition metals, advanced lipid peroxidation end products, advanced glycation end products, and DNA modifications. We have further identified aberrant re-entry of neurons into the cell cycle as a component of neurodegeneration and, more recently, have identified stress granules as a potential, critical manifestation of Alzheimer’s disease. Other areas of investigation include the molecular pathogenesis of prion diseases, including genotype phenotype correlation, and characterization of novel forms of Creutzfeldt-Jakob disease.

Catellini Expertise include oxidative stress as applied to human brain; specifically, redox active transition metals, advanced lipid peroxidation end products, advanced glycation end products, and DNA modifications.

Dr. Inge GrundkeIqbal is Professor and Head of Neuroimmunology at the New York State Institute for Basic Research in Developmental Disabilities Staten Island New York. Dr GrundkeIqbal is a world renowned neuroscientist and Alzheimer disease researcher who has authored/coauthored approximately 200 scientific publications in prestigious American and international journals and books. She has made several seminal discoveries including the abnormal hyperphosphorylation of tau which has opened a whole new area of research in neurodegeneration especially Alzheimer disease and related conditions like Down Syndrome. Her research contributions have won her several US Public Health Service National Institutes of Health and nonfederal research grants and honors Dr GrundkeIqbal received the New York State Governors Award for Woman of Distinction in 1994 the Life Time Achievement Award for Alzheimers Disease Research in 2000 and the TLL Temple Foundation Discovery Award for Alzheimers disease Research in 2001 She was awarded Honorary. Professorship by Tongji Medical University Wuhan PR China in 2001.

Inges research is in neurodegeneration, especially Alzheimer disease and related conditions like Down Syndrome.

Luigi Iuliano received his MD degree summa cum laude and the PostGraduate Diploma in Internal Medicine from Sapienza University in Rome in 1982 and 1987 respectively. He is currently Associate Professor of Internal Medicine and Head of Vascular Medicine Research Lab at the Department of Medical Sciences and Biotechnology Sapienza University of Rome at Latina. His research is published in over 80 peerreviewed papers. He is Associate Editor of Journal of Alzheimer Disease Open Clinical Chemistry Journal and Journal of Geriatric Cardiology. His research interests cover a wide spectrum in the field of oxidative stress related disorders including atherosclerosis and neurodegenerative diseases as well as clinical and epidemiological studies. He is deeply involved in cholesterol and its oxidized derivatives oxysterols metabolism and quantification in varied diseases. He is founder and coordinator of the European Network on Oxysterols Research ENOR a network focusing on the chemistry biology and medical implications of cholesterols and related sterols.

Luigi research interests cover a wide spectrum in the field of oxidative stress related disorders, including atherosclerosis and neurodegenerative diseases, as well as clinical and epidemiological studies.

Eef Hogervorst did her Ph.D. at Maastricht University in age related cognitive decline and treatment at the Department of Psychiatry and Neuropsychology in 1998. She was subsequently employed at the University of Oxford (Oxford Project to Investigate Memory and Ageing, OPTIMA) as a neuropsychologist and epidemiologist and was awarded several grants and prizes for her research into early diagnoses and risk factors for dementia and cognitive decline. Eef did similar research as a Research Associate Professor at the Donald W. Reynolds Department of Geriatrics (ranked 8th nationally) of the University of Arkansas Medical Sciences and at the University of Cambridge (Department of Psychiatry) as Senior Research Associate, before taking on a Chair in Psychology at Loughborough University which is consistently ranked among the top Universities in the U.K. Eef has set-up collaborations with several large multi-centre observational and treatment studies for age related cognitive decline and dementia (EPIC NORFOLK and MRC CFAS in the U.K. and the H ABC, WHIMS and KEEPS studies in the U.S.A and a large cohort in Indonesia). She studies cross cultural clinical diagnostic accuracy of different types of dementias and has developed and validated a computerized expert system and cognitive test battery for this purpose with Dr Bandelow.  Eef is an elected member of the MRC College of Experts for Neuroscience and Mental Health, a member of the European Scientific Referee panel for the European Research Area in Ageing and is often asked to review research proposals (Alzheimer Association, NWO, SPARC etc) and papers in her field (Neurology, JNNP, Arch Neurol, etc). She was invited as a keynote speaker at several conferences (e.g. ICAD). At Oxford Eef was Somerville Junior Research fellow and Blasschko fellow at Linacre College. Eef is an elected young Fellow at the Royal Society of Medicine in London, Editor (Section Head) of the International Faculty 1000, on the editorial board of JAD and has over 100 international  peer reviewed publications.

Eef early diagnoses and modifiable risk and protective factors (e.g. hormones, exercise and nutrition) for dementia and age related cognitive decline; development and validation of cognitive tests and computerized diagnostic systems.

Bilotta education was as Medical Doctor Degree (110/110 cum Laude) in University of Rome La Sapienza, Fellowship in Cardiology (70/70 cum Laude), University of Rome La Sapienza, Biomedical Engineering. Interdeparment Post University Degree in Methods for the analysis of biomedical signals and images. (110/110 cum Laude), University of Rome La Sapienza, Fellowship in Anesthesiology and Intensive Care (70/70 cum Laude), University of Rome La Sapienza, Philosophie Doctor (Ph.D.), Cardiorespirotory physiopathology, University of Rome La Sapienza.

Bilotta research interests include Anesthesiology, Critical Care, Pain Medicine, Neuroanesthsiology and Neurocritical care.

Dr. Gary W. Arendash received his doctoral training at the University of California, San Francisco Medical Center, specializing in Physiology and Neuroscience. He then went to the UCLA Brain Research Institute, where he resided for a 3 year post doctoral fellowship. Thereafter, he joined the USF Department of Biology faculty, where he eventually became a Full Professor. Several years ago, Dr. Arendash became a Research Professor at USF and the FADRC. As such, he has been able to devote 100% of his effort to research. Dr. Arendash serves on the editorial board for several journals, including the Journal of Alzheimer Disease. As Director of the FADRC Mouse Core, Dr. Arendash oversees a Core that has established itself as pre eminent in the field of behavioral assessment of transgenic mouse models for Alzheimer Disease (AD). Since its inception with the FADRC in April, 2005, the Core has published over 20 peer-reviewed papers involving behavioral characterization of various AD mouse models and their use in developing therapeutics to protect against and/or treat AD. In analyzing behavioral data from multiple cognitive-based tasks, the Core has pioneered both higher levels statistical analysis and data mining approaches (e.g., artificial neural nets) all of which provide a very sensitive assessment of behavioral performance in AD transgenic mice. Dr. Arendash primary goal is to develop effective, safe, and readily available therapeutics in his AD mouse models that can be quickly advanced to clinical trials. This translational goal of bridging the gap between basic and clinical AD research offers the best hope of finding an effective therapeutic against AD. Dr. Arendash research efforts involve extensive collaborations with researchers throughout USF, Florida, the United States, and the world. As a research enterprise without walls, the FADRC Mouse Core, Dr. Arendash laboratory, and associated expert collaborators provide the scope of multi-disciplinary research that could be key to unlocking the mysteries of AD and finding an effective therapeutic.

Gary research interests include Neuroscience, Neurobiology of Aging and Animal Models for Degenerative Brain Diseases, Therapeutics against Alzheimer Disease and Brain aging.

Ilya education of M.Sci. in Physics, Leningrad Polytechnical Institute, Dept. of Physics and Mechanics, Leningrad, USSR, Ph.D. in Cell Biology, March of 1992, Institute of Cytology Russian Academy of Sciences, St. Petersburg, Russia. D.Sci. in Cell Biology, Institute of Cytology Russian Academy of Sciences, St. Petersburg, Russia.

Ilya research interests include Alzheimer’s disease, Physiology, Polytechnic studies.

Elliot’s education of Postdoctoral Fellow, Harvard Medical School, Ph.D., Downstate Medical Centre, SUNY, New York, M.A, Kansas State University, Manhattan, Kan., B.A, Hunter College, New York, 1969.

Elliot’s research interests include Pathological Conditions Signs and Symptoms.

James R. Bamburg is a Professor of Biochemistry and Molecular Biology at Colorado State University where he has served on the faculty for 40 years.  He was a founding member and served 14 years as director of the Molecular, Cellular and Integrative Neuroscience program at Colorado State University. He has published more than 180 papers, most focused on the structure and regulation of the neuronal cytoskeleton. He serves on several editorial boards including senior and section editor on neuroscience journals.  He discovered the first member of the ADF/cofilin family of actin regulatory proteins over 30 years ago and has made seminal contributions to understanding their biochemistry, phospho-regulation by cell signaling, and their role in neuronal cell biology.  His current research is focused on the role and regulation of these proteins in synaptic function and in synapse loss in neurodegenerative diseases. For the past 10 years his major focus has been on Alzheimer and Huntington diseases.

James research interests includes, Role of the actin cytoskeleton in growth cone pathfinding and dendritic spine formation and function; role of cofilin-actin rods in synapse loss during neurodegenerative disease progression; age-related changes in actin dynamics and actin binding protein function.

Jane Joseph received her PhD in Psychology from the University of Virginia and completed a postdoctoral fellowship at Georgetown University. After a decade as a faculty member at the University of Kentucky. Dr. Joseph is now a Full Professor in the Department of Neurosciences at the Medical University of South Carolina. She also serves as the director of the Neuroimaging Division in the Neurosciences Department. Her research interests are fairly broad within the discipline of cognitive neuroscience and she collaborates with individuals in several different departments and colleges at the University of Kentucky and the Medical University of South Carolina. Dr. Joseph’s lab has been and continues to be funded by grants from the National Science Foundation, the National Institutes of Health. She is currently serving on the Editorial Board for the Journal of Neuroscience Methods and has served as a grant reviewer for the National Science Foundation and National Institutes of Health.

Dr. Joseph’s research interests center around a general theme of understanding the brain basis of cognition in healthy brain development and aging and in neurodegeneration and psychiatric disease.

Sambamurthys research aims to understand the basis of neurodeneration in age-related neurodegenerative diseases. We are using multiple approaches in several disease models to systematically uncover the common pathways in neurodegeneration and to identify methods to prevent or treat the process. A key focus on the lab has been Alzheimer’s disease (AD). In this disease, there is a characteristic deposition of the 42-residue amyloid β protein (Aβ42) demonstrating the failure of protein homeostasis in the brain.  Similar protein accumulation is characteristic of a number of other degenerative diseases in the CNS such as age-related macular degeneration (ARMD) as well as somatic tissues as in islet amyloid. The general assumption has been that the neurodegeneration is caused by specific toxicity of the accumulated protein aggregates.  Interestingly cholesterol has been identified as a risk factor in AD and also in ARMD. Both diseases show extracellular deposits of amyloid. Our studies are evaluating the role of amyloid and the secretases in AD as well as retinal generation to understand common mechanisms of degeneration. We hope and expect that the detailed evaluation of the common pathways of degeneration in AD and forms of retinal degeneration will identify ways to prevent and treat these devastating diseases.

Sambamurthy′s research aims to understand the basis of neurodeneration in age-related neurodegenerative diseases.

George has been involved in diagnosis and treatment of Alzheimer’s disease and other dementia patients since 1980. George also has been involved in both treatment research and research related to the symptoms of Alzheimer’s disease for more than 20 years. In 1985 he started the first community Alzheimer’s disease Brain Bank in the Saint Louis area and shortly thereafter he started our clinical trial program. George have been actively involved in NIH funded studies looking at a variety of treatments for Alzheimer’s disease, including omega 3 fatty acids, Divalproex, vitamin E and others. At present time George is the PI for NIH funded IVIg Alzheimer’s disease treatment Trials and George also the PI for a series of monoclonal antibody studies in patients with mild Alzheimer’s disease. George have published extensively in the field and have publication in press relative to the prevalence and treatment of Parkinson’s disease Dementia. 

George′s Research interests include Alzheimer′s disease, Dementia.

A native of Bergamo, Italy, Dr. Pasinetti received both his M.D and Ph.D. from the University of Milan in Italy.  He is currently the director of the Brain Institute Center of Excellence for Novel Approaches to Neurotherapeutics at the Mount Sinai School of Medicine, and he also holds the position of Saunders Family Professor in Neurology. Dr. Pasinetti has been awarded more than 30 grants, including funding from the National Institutes of Health, and he has published more than 160 groundbreaking articles. Dr. Pasinetti has also been the recipient of many awards including The Alzheimer’s Association’s Zenith Award.

Pasinetti′s research into one of mankind’s most puzzling diseases has the potential to unlock one of the greatest mysteries of the human mind. His expertise in Alzheimer’s disease (AD) and the molecular mechanisms influencing clinical dementia’s onset and progression made one of the world’s most sought after leaders in this field. His research experience in neurodegenerative diseases offers unprecedented possibilities towards the discovery of novel strategies in the treatment of AD, as well as other diseases and conditions. Along with this line of study, the proposed research application seeks to investigate the therapeutic validity of delaying the onset and possibly slowing the progression of AD, dementia, and amyloid neuropathology

Ramassamy’s education of Post-doctorat in Neurobiology of Alzheimer’ disease, Douglas Hospital Research Center, Univ. McGill (Montréal, Canada), Ph.D in Neurosciences, Univ. Des Sciences de Rouen (France), M.Sc, Pharmacology, Faculté de pharmacie Paris V (France).

Ramassamy′s research interests includes Oxidative stress in aging, neurodegenerative disorders and Alzheimer’s disease, Neuroprotective effects of polyphenolic and nutraceutical compounds.

Yong Shen did his B.Sc in Physiology in Nanjing university, M.sc in Neurophysiology in Shanghai institute of physiology, Academy of sciences and Ph.D in neuroscience in State university of Newyork.

Yong shen′s research interests include Alzheimer′s Disease, Neuro Science, Neurology.

Colin had his Ph.D. from the University of Rochester in the Department of Neurobiology and Anatomy and did my post-doctoral studies in the Alzheimer Research Laboratory at Case Western Reserve University. He joined the Dept. of Pharmacology, Physiology and Therapeutics at the University of North Dakota as an Assistant Professor in 2000 and was promoted to Associate Professor in 2007. His work focuses on understanding the mechanisms that contribute to the inflammatory changes characteristic of the chronic neurodegeneration that occurs in Alzheimers and Parkinsons disease. In particular, his laboratory works to identify how the brains immune cells, microglia, may be contributing to the pathophysiology of these conditions.

Colins Research Interests includes Microglia, Cytokine, Signaling, Kinase, Neurotoxicity, Neuroprotection, Inflammation, Neuroinflammation, Amyloid, Synuclein.

Dr. Jack de la Torre is a leading authority in the field of Alzheimers disease (AD). In 1993, he first advanced the concept of AD as a vascular disorder with neurodegenerative consequences in a series of papers that culminated in the CATCH (critically-attained threshold of cerebral hypoperfusion) vascular hypothesis of AD. The vascular hypothesis of AD had a profound impact and influence on research studies involving epidemiology, neuroimaging, neuropathology and therapeutics that continue to clarify the pathophysiology and pathogenesis of Alzheimer dementia. Dr. de la Torre has edited 7 major volumes on the subject of vascular factors in AD and published a substantial number of papers on neurodegeneration, neuropathology and CNS trauma. He has held professorial appointments in the Departments of Neurosurgery at the University of Chicago, Northwestern University, University of Ottawa, and in Pathology at Case Western Reserve University. Dr. de la Torre continues his active research on Alzheimers disease as a Senior Scientist at the Banner Sun Health Research Institute in Arizona.

Jacks research studies involving epidemiology, neuroimaging, neuropathology and therapeutics that continue to clarify the pathophysiology and pathogenesis of Alzheimer dementia.

Dr. Othman Ghribi is an Associate professor at the Department of Pharmacology, Physiology and Therapeutics, University of North Dakota School of Medicine and Health Sciences, USA. He obtained his PHD degree in Neuropharmacology from Rene Descartes University, Paris, France in 1994. He published four book chapters, invited review papers and has more than 50 publications in different peer reviewed journals. Dr. Ghribi holds grants from the Centers of Biomedical Research Excellence and the National Institute of Environmental health Sciences/The National Institute of Health. Dr Ghribi obtained the Alzheimers and Related Diseases Research Award from the Virginia Center on Aging as well as the Dean David Wilson Academic Award in Neuroscience from the University of North Dakota.

Othman Ghribis Interests include role of the diet and environmental factors in Alzheimers and Parkinsons diseases, Tyrosine hydroxylase, alpha-synuclein, LXRs, Estrogen receptors, Oxysterols, Endoplasmic reticulum stress, Apoptosis, IGF-1, Leptin.

Stephen did his B.A. Cornell University, College of Arts and Sciences, Ithaca, NY (Psychology). Ph.D. Mt. Sinai Medical Center, New York, NY (Neuroscience).

Stephens interests include neurodegeneration, single cell RNA analysis, and lesion induced synaptic plasticity.

Suzanne de la Monte is a physician scientist who directs basic and translational research in the laboratory. I also perform clinical service work in Neuropathology. This activity includes teaching residents and students. Her research efforts are mainly focused on understanding the role of insulin and insulin-like growth factor resistance in relation to neurodegeneration caused by Alzheimer′s disease and chronic alcohol abuse.

Suzanne is interested in the molecular mechanisms of programmed cell death as well as the role of aspartyl (asparaginyl) beta hydroxylase (AAH) in cell motility and invasiveness of tumor cells as well as neuronal cells. In addition, the studies focus on growth factor signaling through IRS 1 and the role of this pathway in oncogenesis.

Kebreten Manaye is an Associate Professor in the Department of Physiology and Biophysics at the Howard University College of Medicine where she has been a faculty member for eleven years. After earning her medical degree from the University Of Aristotle School Of Medicine in Thessalonica Greece. Dr Manaye joined the Department of Psychiatry at the University of Texas, Southwestern Medical Center in Dallas as a postdoctoral fellow in 1986 In 1990 she became an assistant professor in the department before moving to Howard University in 1999. Her publications have appeared in journals such as the Journal of Comparative Neurology Biological Psychiatry and Neuropharmacology. She is an active member of several professional organizations including American Association for the Advancement of Science AAAS the Society for Neuroscience International Alzheimer Association International Brain Research Organization and the New York Academy of Sciences. She currently serves as an Associate Editor for the Journal of Alzheimer Disease and she also serves on the Board of Directors for the International Behavioral Research Press and Sinq Neuroimaging Systems Inc

Dr. Manaye research program focused on understanding the mechanisms that underlie neurological illnesses associated with brain aging. For these studies, she has used a diverse range of stereological, neuroimaging, molecular, biochemical, and behavioral approaches to understand normal aging of the brain, neuropathology of aging, and comparative work aimed at elucidating neuronal mechanisms of neurodegenerative disorders, including Alzheimer and Parkinson disease, and to develop potential approaches to prevent or delay the onset of these disorders. Her main research interest is to investigate the mechanisms of neuropathology and treatments of neurodegenerative disorders using in vivo and in vitro models. She has found a mouse model that exhibits similar neuropathology to that found in these neurodegenerative disorders. She has further found that 17 estradiol is an effective mediator of neuroprotection in this model. Her long term goal of these studies is the development of novel strategies for the therapeutic management of patients afflicted with AD and PD.

Dr. Nelson is an experimental neuropathologist whose research focuses upon the molecular neurochemistry of the human brain in health and in neurodegenerative disease particularly in the context of RNA biology. The study of small regulatory RNAs is a relatively new and unexplored research field with much potential. Dr. Nelson work has focused upon the predominant small regulatory RNA subtype in humans and in all animals, which are termed microRNAs miRNAs. MiRNAs subserve fundamental biological functions in all animals studied. He invented new techniques to analyze and manipulate these small molecules, and studies how miRNA biology is altered in neurodegenerative diseases. Dr. Nelson seeks both to understand how miRNAs contribute to disease pathogenesis, and to explore how specially designed RNAs may be applied for therapeutic strategies.

Dr. Nelson work has focused upon the predominant small regulatory RNA subtype in humans (and in all animals), which are termed microRNAs (miRNAs). MiRNAs subserve fundamental biological functions in all animals studied. He invented new techniques to analyze and manipulate these small molecules, and studies how miRNA biology is altered in neurodegenerative diseases. Dr. Nelson seeks both to understand how miRNAs contribute to disease pathogenesis, and to explore how specially-designed RNAs may be applied for therapeutic strategies.

Daffner education of masters was in Harvard Medical School, Boston and B.A in Harvard College, Cambridge.

Daffner research interests include neurology, neurosciences and Brain diseases.

Vanessa education of M.D awarded by University of Hamburg, Germany, Ph.D awarded by University of Hamburg, Germany.

Vanessa Research interests include Movement Disorders, Parkinson Disease, Dystonia.

Craig S. Atwood is an Associate Professor of Medicine at the University of Wisconsin and a Health Science Specialist with the Geriatric Research, Education and Clinical Centre at the William S. Middleton Memorial Veterans Administration Hospital in Madison. Dr. Atwood completed his Ph.D. in Biochemistry from the University of Western Australia in Perth, Australia prior to postdoctoral fellowships at the National Cancer Institute, NIH, Bethesda, and Massachusetts General Hospital, Charlestown. He held faculty positions at Harvard Medical School and Case Western Reserve University prior to his current appointment where he directs the research program of the Laboratory for Endocrinology, Aging and Disease. He has published over 200 scientific articles, has served on numerous review boards and is an Editor of more than 20 scientific journals including the Journal of Biological Chemistry. In 2006 he received the Zenith Fellows Award from the Alzheimer Association in recognition of his research.

Dr. Atwood has broad research interests related to the endocrinology of embryogenesis, adulthood and senescence as elaborated upon in The Reproductive Cell Cycle Theory of Aging.

Garth’s Education of B.Sc. in Biology was in McGill University at 1979 and his Ph.D. in Biology at Yale University in 1985.

Garth will be studying the cell biology of axonal regeneration, neuronal polarization, and neurodegeneration. For these studies, we have developed a unique model system in which proteins, enzymes and metabolic inhibitors are microinjected into giant identified neurons in the brain of the sea lamprey, a primitive vertebrate. This model system allows detailed analyses of neuronal pathways previously inaccessible due to the complexity of the human brain. Ultimately, what we learn from this model system will help in elucidating the cellular mechanisms responsible for the development of neurodegenerative conditions in humans.

Hemachandra Reddy is an Associate Scientist at the Oregon National Primate Research Center of Oregon Health and Science University (OHSU). He was a commonwealth scholar (1990-1993) before receiving his Ph.D. (1994) in human genetics from London University. He did his postdoctoral training (1995-2000) at the National Human Genome Research Institute, NIH, Bethesda. Dr. Reddy has received several awards and honors, including Commonwealth Scholarship from Commonwealth Commission; Fellows Award for Research Excellence from NIH; Alzheimer Award from the Journal of Alzheimer’s Disease, and Technology Innovations Award from OHSU. Dr Reddy has served on several NIH study sections, including the sections – CDIN and NOMD. Dr Reddy is an editorial board member for 12 journals and he is an internationally recognized expert in mitochondrial biology, and neurodegenerative diseases. Currently, the Reddy laboratory is focusing on unraveling the connection between amyloid beta and synaptic damage, and amyloid beta and mitochondrial oxidative damage in AD.

Hemachandra research interests include Molecular and Cell Biology, Gene Expression Analysis, Transgenic Mouse, Models, Aging, Neurodegenerative Diseases, Mitochondrial Biology, Mitochondrial Function/Dysfunction and Mitochondrial Therapeutics.

Mikko’s education of M.Sc, Biotechnology (1995); Department of Biochemistry and Biotechnology, Faculty of Natural Sciences and Environmental Sciences, Kuopio University, Finland, Ph.D, Neuroscience (2001); Department of Neuroscience and Neurology, Faculty of Medicine, Kuopio University, Finland. Doctoral thesis in the field of neuroscience: “A molecular genetic study of factors involved in Alzheimer’s disease" Docent (Adjunct Professor), Molecular genetics (2005); Faculty of Medicine, Kuopio University, Finland.

Mikko′s research interests include Alzheimer′s disease, Neuroscience and Molecular genetics.

Dr. Praticò received his M.D. from the University of Rome “La Sapienza”, School of Medicine where he also completed the residency program in Internal Medicine. After receiving a European Research Award fellowship, he spent two years of post-doctoral training at the University of Dublin. In 1994, he joined the University of Pennsylvania as Research Associate, where he was promoted to Assistant Professor of Pharmacology. In 2007, he moved to Temple University in Philadelphia as an Associate Professor of Pharmacology, Microbiology and Immunology. He has authored over 177 articles in peer-reviewed scientific journals, authored more than 16 review articles and more than 10 book chapters. He has received many awards for his research accomplishments including the Irvine H. Page Award, Neurosciences Education and Research Award, and The Zenith Award from the Alzheimer’s Association.
 

Pratico′s main research interest is clinical pharmacology with a special focus on the cellular and molecular aspects of oxidative neurobiology, and their role in the pathogenesis of chronic neurodegenerative diseases such as Alzheimer’s disease.

Dr. Head received a M.A in Psychology and a Ph.D. in Neuroscience from the University of Toronto, Canada. She received postdoctoral training at the Institute for Brain Aging & Dementia at the University of California – Irvine. She was co-leader of the Neuropathology Core of the University of California Irvine Alzheimer’s Disease Research Center and was Director of the Institute’s Brain Bank. Dr. Head moved to UK in January of 2009 and is currently an Associate Professor at the Sanders-Brown Center on Aging. 

The focus of Dr. Head’s research team is to identify interventions in animal models that may prevent the onset and/or progression of Alzheimer disease in Down syndrome and in the general population.

Yasumasa Graduated in Kyushu University School of Medicine, Fukuoka, Japan, Resident, Department of Neurology, Kyushu University Hospital Neurologist, National Beppu Hospital, Oita, Japan, Research fellow, National Institute of Neuroscience, NCNP, Tokyo, Resident, Department of Neurology, Kyushu University Hospital, Visiting Scientist, Case Western Reserve University, Cleveland, OH, USA, Visiting Scientist, Mayo Clinic Jacksonville, Jacksonville, FL, USA, Neurologist, Department of Neurology, Iizuka Hospital, Fukuoka, Research Associate, Department of Neurology, Kyushu University, Assistant Professor, Department of Neurology, Kyushu University, Associate Professor, Department of Neurology, Kyushu University

Yasumasa′s Research interests include Neurology, Neurobiology, Neurochemistry, Neuroimmunology, Research area: Cell Biology, Pharmacology, Biochemistry in Alzheimer research.

Efrat Received M.Sc. and Ph.D. from The Hebrew University in Jerusalem, Israel. Was a postdoctoral fellow in the Department of Biochemistry followed by assistant research scientist in the Department of Pathology, both at New York University School of Medicine, New York, New York. Currently is an Associate Professor in the Departments of Psychiatry and Pharmacology, New York University School of Medicine, New York, New York and in the Center for Dementia Research, Nathan S. Kline Institute, Orangeburg, New York.

Efrat′s Research interests are treatment targets for Alzheimer’s Disease and  other neurodegenerative disorders. The focus is on discovering genetic mutations and allelic variations involved in hereditary forms of  amyloidoses; characterizing the regulation of amyloid precursor proteins processing; defining processes involved in the conversion of  soluble protein to the insoluble, oligomeric and fibrillar forms; identifying factors that inhibit oligomerization and fertilization of amyloid proteins; and identifying factors that prevent disease-driven neurodegeneration

Dr. Joseph Quinn is an Associate Professor of Neurology at Oregon Health and Sciences University and a staff neurologist at the Portland VA Medical Center.  He completed his undergraduate studies in Biochemical Sciences at Harvard University, his MD at University of Southern California, his internship at LA County Hospital, and his neurology residency at Oregon Health and Sciences University. He has been on the faculty in Oregon since 1994. With grant support from the NIH and from the VA, he has conducted laboratory and clinical research on a number of such candidate therapies for Alzheimer’s disease, including ginkgo biloba, melatonin, lipoic acid, ibuprofen, resveratrol, coenzyme Q, copper chelation, and the omega 3 fatty acid DHA. His research is described as “translational”, which means Dr Quinn has no original ideas but instead attempts to bring established ideas from the laboratory to clinical trials. In some cases, such as copper chelation therapy, this means conducting animal studies to determine if clinical trials are warranted. In other cases, such as ibuprofen, this means conducting novel pilot clinical trials utilizing surrogate markers of disease in order to determine if a large scale clinical trial is warranted.  And in yet other cases, such as a national multi-center trial of DHA , this means designing and supervising a full scale clinical trial based on preclinical animal studies conducted and reported by other investigators. The specific positions held by Dr Quinn to support these research efforts include Biomarker Core Leader, Associate Clinical Core Leader, and Clinical Trials director for the NIA-funded Oregon Aging and Alzheimer’s disease center. Dr Quinn is also co-director of the Portland Parkinson’s Disease Research, Education, and Clinical Care Center.

Joseph′s research interests are clinical trials, biomarkers, and animal models in Alzheimer′s disease, and cognitive impairment in Parkinson′s disease.

Jeffrey M. Burns, M.D is an associate professor of Neurology at the University of Kansas Medical School where he directs the KU Alzheimer and Memory Program.  Dr. Burns graduated with a degree in English and Japanese from the University of Notre Dame and attended medical school at the University of Kansas School of Medicine. After medical school, Dr. Burns completed his residency in neurology at the University of Virginia followed by a post-doctoral fellowship at the Alzheimer Disease Research Centre at Washington University in St. Louis. The KU Alzheimer and Memory Program support numerous research projects investigating Alzheimer’s disease and aging. Dr. Burns’ overall research interest is to better understand how lifestyle issues such as diet and physical fitness impact brain aging and the progression of Alzheimer’s disease. Dr. Burns also directs the Clinical and Translational Science Unit.  His research is supported in part by several grants from the National Institutes of Health. 

Dr. Burns’ overall research interest is to better understand how lifestyle issues such as diet and physical fitness impact brain aging and the progression of Alzheimer’s disease.

Dr. Videnovic obtained his M.D at the University of Belgrade School of Medicine, where he subsequently completed an internship in Internal medicine followed by a residency in Anatomic pathology. From 1998 to 2000 he was a postdoctoral fellow in the Department of Pharmacology at the University of Illinois in Chicago, where he worked on the neurobiology of the sleep apnea syndrome. He subsequently moved to the Rush Alzheimer′s Disease Center in Chicago, where he worked on several NIH funded clinical-pathological studies of aging. Dr Videnovic completed an internship in Internal medicine at MCP Hahnemann University Hospital in Philadelphia, and a Neurology residency at Northwestern University Feinberg School of Medicine in Chicago where he served as chief resident. Subsequently he trained in Movement Disorders at Rush University Medical Center in Chicago, and sleep medicine at Northwestern University. He obtained a Master of Science degree in clinical research from the Rush Graduate College in 2007. He was appointed as Assistant Professor of Neurology at Northwestern University Feinberg School of Medicine in July 2007. Dr. Videnovic is a member of the American Academy of Neurology, the Parkinson Study Group, and the American Academy of Sleep Medicine. Dr. Videnovic cares for patients with Parkinson′s disease and various movement disorders. He is a principal investigator and co-investigator on several clinical trials in the field of Parkinson′s disease and movement disorders. His research focuses on sleep dysfunction in neurodegenerative disorders, particularly Parkinson′s disease.

Aleksander research focuses on sleep dysfunction in neurodegenerative disorders, particularly Parkinsons disease.

Dr. Valeria Drago is an Italian Neurologist. She graduated at University of Messina School of Medicine in 2001. In the same institution she took her residency (cum laude) in Neurology. She has done a three year fellowship in Behavioral Neurology with Dr. Kenneth Heilman at University of Florida, College of Medicine, Gainesville, FL, USA where she joined the faculty as a full time Adjunct Assistant Professor (2006-2010). She came back to Italy on January 2010 and she is currently holding a research position at the Center Fatebenefratelli in Brescia (Italy), and a courtesy appointment at UF as Adjunct Assistant Professor. She has several national and international collaborations including the department of Neurology at University of Bologna where she is currently at her 3rd year of Ph.D. The majority of her research has been devoted to investigate attention and creativity in degenerative diseases, particularly Alzheimer′s and Parkinson′s diseases.

Valeria Dragos research has been devoted to investigate attention and creativity in degenerative diseases, particularly Alzheimer′s and Parkinson′s diseases.

Cannon received his B.A., M.A. and Ph.D. from the University of Tennessee, Knoxville. He is an Assistant Research Professor in the Department of Psychology and director of the clinical neuroscience laboratory at UT and director of the cognitive neuroscience laboratory at the Cole Neuroscience Center, located at the University of Tennessee Memorial Medical Center. He completed his Ph.D. in experimental psychology with an emphasis in neuroscience methods, neurophysiology and biological psychology. He is author of several book chapters and has published numerous neuroscience papers in peer-reviewed journals, including the first work demonstrating that human beings can learn to change the electrical activity in specific regions within the cortex using spatial specific neuro-operant learning. Cannon has received awards for research presentations and was recently nominated by the National Institute of Drug Abuse for a young investigator award. He has collaborated on a book chapter about the efficacy of neurofeedback for treatment of substance use disorders, and is developing statistical models for reporting psychotherapy and addiction treatment efficacy. He received several awards during his graduate training, including the Cureton Award for outstanding scholarship in the areas of psychometrics and neuropsychology. Cannon has presented research at Columbia University and Harvard Medical School. More recently, he has introduced a standard protocol for assessing treatment outcomes for psychiatric syndromes. He has developed chemical dependency assessment instruments and a treatment model incorporating standardized group therapy and spatial-specific neurofeedback training.

Rex Cannon can discuss issues related to the brain, including clinical neuroscience, biological psychology, self-regulation and electroencephalogram (EEG) source localization. Cannon also can discuss low resolution brain electromagnetic tomography (LORETA), neuroimaging, neurocognitive testing, psychometrics and statistical modeling.

Dr. Anekonda received a doctoral degree from the University of California (UC) at Berkeley, postdoctoral training from the UC Davis, and Alzheimer disease and retinopathy related research experiences from the Oregon Health and Science University (OHSU) at Portland, Oregon. He currently serves as Assistant Professor in the Department of Neurology at OHSU. The long-term goal of his research is to define the neuroprotective mechanisms of herbal and non-herbal drugs at molecular and cellular levels and determine their treatment options for Alzheimer disease. The molecular pathways downstream of beta amyloid production are of particular interest: intracellular calcium, tau pathology, antiaging sirt1 and autophagy.

Neuroprotective mechanisms by herbal and non-herbal drugs against Alzheimer′s disease pathology. Age-related neurodegeneration; beta amyloid and tau pathology; autophagy pathway; mitochondrial functions; anti-aging sirtuin and anti-inflammatory pathways; mechanisms of calorie restriction (CR) and CR mimetics (CRMs); in vitro and in vivo models of Alzheimer’s disease.

Inga received her PhD in Neuroscience at the University Of Kuopio, Finland in 2002 and did her first postdoctoral training in stroke research there. In 2004 She joined the University of Alabama at Birmingham in the postdoctoral training Program in Vascular Biology and Hypertension, examining the relation between hypertension and the development of AD. Presently, her lab continues these studies, and we are also focusing on the role of vascular pathology in the white matter, the development of cognitive deficits and AD. Currently, I am an Assistant Professor in the Dept. of Cell Biology at the University of Alabama at Birmingham.

Inga is interested in the role of white matter pathology in the development of age related cognitive deficits. A second research interest is the role of vascular pathology in Alzheimer disease, especially the relation between hypertension and age-related cerebral dysfunction and Alzheimer disease.

Arabinda education was as follows Research Associate, Molecular Biology Duke University Medical Center, Durham, NC, Postdoctoral Fellow, Biochemistry and Molecular Biology Medical University of South Carolina, Charleston, SC, Postdoctoral Fellow, Neurosciences Neurology Medical University of South Carolina, Charleston, SC.

Arabinda Research interests includes the development of novel therapeutic strategies for Spinal Cord Injury (SCI), Traumatic Brain Injury (TBI), Epilepsy, Glaucoma, and Multiple Sclerosis (MS), Analysis of the roles of calpain, and protein kinases involved in the alteration of vascular endothelial growth factor (VEGF) in SCI, TBI, and Experimental Autoimmune Encephalomyelitis (EAE), a model of MS, The development of new drugs for cancer treatment and the translation of these findings into clinical trials. Focusing mainly on glioblastoma multiforme (the most common and devastating of the human brain tumors) and neuroblastoma.

Murphy did his B.Sc. in biochemistry at University of Toronto, Ontario, Canada; M.A. in psychology at University of Toronto, Ontario, Canada; Ph.D. in Neuroscience at University of Toronto, Ontario, Canada and Post-Doctoral Training.

Murphy′s research interests include neuroscience, psychology, Alzheimer′s Disease.

Mitchell Clionsky, Ph.D. ABPP(CN) is a board certified clinical neuropsychologist with more than 30 years experience in hospital and outpatient settings. He directs a multi-specialist outpatient practice in Springfield, MA that specializes in the evaluation and management of dementia, traumatic brain injury, attention deficit problems, and other neurologically-related illnesses. Integration of clinical care and research is a primary focus of this practice. He and his wife/partner, Emily Clionsky, M.D, are the developers of the Memory Orientation Screening Test™, a 5-minute neuropsychologically-based test for primary care physicians and specialists to use in identifying dementia and tracking its level over time. In addition, Dr. Clionsky developed tests for patient- and informant-awareness of cognitive impairment, a measure of patient ability for to learn and recall practical list information, and a test of logical reasoning.

Mitchell developed patient- and informant-awareness of cognitive impairment, a measure of patient ability for to learn and recall practical list information, and a test of logical reasoning. His research impacts practical decisions regarding novel treatment approaches and adherence to treatment.

Gary Aston Jones is a Professor and the Murray Chair of Excellence in Neuroscience in the Department of Neurosciences at the Medical University of South Carolina (MUSC), where he is also the Director of the Carolina Primate Center. Previously, he was a Professor in the Department of Psychiatry and the Director of the Laboratory for Neuromodulation and Behavior at the University of Pennsylvania, and the Director of the Neuroscience of Addiction Research Center at Penn. Dr. Aston-Jones earned his Ph.D. in neurobiology in 1981 from the California Institute of Technology and his B.A. in 1973 from the University of Virginia. He served as a Postdoctoral Fellow from 1980 to 1982 at the Salk Institute. His recent honors include serving as the current Chairman of the Neurobiology of Motivated Behavior CSR Review Group, receiving a 2003 National Institute on Drug Abuse Merit Award, and being the Keynote Speaker at a 2002 Neuroscience Retreat at Vanderbilt University. Dr Aston Jones primary research interests are in the brain neuromodulatory systems, and their roles in cognitive performance, sleep and waking, drug abuse, and affective disorders. He uses a multidisciplinary approach, primarily involving single unit neurophysiology, neuroanatomy and behavioral neuropharmacology in rats and monkeys. He and his colleagues have recently described a role for the brain noradrenergic locus coeruleus system in decision processes, in the circadian regulation of sleep and waking, and in depression. Other of his lab recent work also reveals a key role for the A1/A2 noradrenergic brain system innervation of the ventral forebrain in the affective response to drug withdrawal, and also indicates an important role of this and related systems in the drug seeking that accompanies protracted opiate withdrawal.

Dr. Aston Jones primary research interests are in the brain neuromodulatory systems, and their roles in cognitive performance, sleep and waking, drug abuse, and affective disorders. He uses a multidisciplinary approach, primarily involving single unit neurophysiology, neuroanatomy and behavioral neuropharmacology in rats and monkeys.

Dr. Flinn was the chair of the Department of Psychology from 1984 to 1995. During her tenure, the department was ranked as one of the most improved programs by the National Chronicle of Higher Education. After stepping down as chair, she became the coordinator of the biopsychology concentration and developed the concentration in biopsychology in the Ph.D in psychology. In 2006, she took over the newly approved undergraduate B.S in neuroscience. The first 3 students graduated in 2009, and there are now over 100 students in the program.

Dr. Flinn’s research focuses on the role of metals in both behavior and physiology. Her research has emphasised the roles of zinc, copper and iron in anxiety, in learning and memory in general and in Alzheimer’s disease specifically, and also in macular degeneration. Her research has included developing genetically modified mice which model late onset Alzheimers disease, the most common form of the disease.

Peters Research Interests include Brain Tumors, Epilepsy, Movement Disorders, Radiosurgery

Robert Perneczky received his M.D degree in 2001 and his Ph.D degree in 2004 from the Technische Universität München (TUM) in Munich, Germany. He worked as a registrar at the Department of Psychiatry and Psychotherapy from 2002 on and became a board certified Psychiatrist in 2009. He is currently an associate professor and head of the research laboratory at the Department of Psychiatry at TUM. Perneczkys research is published in over 70 peer-reviewed papers and he has been awarded several prestigious research awards for his studies. He is associate editor of Journal of Alzheimer’s Disease, Open Longevity Science, and Open Journal of Nuclear Medicine; and member of the European Alzheimer Disease Consortium and the German Competence Network Dementias. Perneczkys main research interests cover a wide spectrum in the field of neurodegenerative disorders including functional and structural neuroimaging, cerebrospinal fluid biomarkers, neurogenetics, and clinical as well as epidemiological studies. He is especially interested in the hypothesis of cognitive and brain reserve.

Perneczkys main research interests cover a wide spectrum in the field of neurodegenerative disorders including functional and structural neuroimaging, cerebrospinal fluid biomarkers, neurogenetics, and clinical as well as epidemiological studies. He is especially interested in the hypothesis of cognitive and brain reserve.

Ubaldo Armato obtained Degree in Medicine & Surgery with Honors (Padua, July 1967). State qualification to medical practice (Padua, March 1968). Diploma in Haematology (Padua, November 1969), Diploma in Internal Medicine with Honours (Padua, November 1975). Full Professor of Histology & Embryology at the University of Verona Medical School (Dentistry: July 1986-October 1987; Medicine & Surgery: from November 1987 to date), Verona, Venetia, Italy. Head of the Histology and Embryology Unit, Dept. Biomedical & Surgical Sciences, Verona University from January 1999 to Januay 2009. Head of the Histology and Embryology Section, Dept. Life and Reproduction Sciences, Verona University from February 2009 to date.

Ubaldo Armato research interest include Embryology, Alzheimers Disease, Neurodegeneration and Neurointegration.

Abha Chauhan, Ph.D., is the Head of the Developmental Neuroscience Laboratory at the New York State Institute for Basic Research in Developmental Disabilities (IBR), Staten Island, New York. She is also adjunct doctoral faculty member of the Neuroscience Subprogram at the Graduate Center of the City University of New York. Dr. Chauhan received her B.S. (Chemistry Honors) in 1976 from the University of Delhi, her M.S. (Biochemistry) in 1978, and Ph.D. in 1982 from the Department of Biochemistry, Postgraduate Institute of Medical Education and Research, Chandigarh, India. From 1983 to 1984, she worked as a Research Associate at the Mount Sinai School of Medicine, New York. Dr. Chauhan then joined the Department of Neurochemistry at IBR, where she has over 60 publications in the fields of membrane biochemistry, oxidative stress, signal transduction, Alzheimer’s disease, and autism. Dr. Chauhan has been awarded research grants as a principal investigator from the Department of Defense, Autism Speaks, Autism Research Institute, and California Walnut Commission, and as a co-principal investigator from NIH. Recently, she served as the editor of the book entitled Autism: Oxidative stress, Inflammation, and Immune Abnormalities. Dr. Chauhans publications include reports on calcium traversal across membrane bilayer, the role of phosphoinositides in the activation of protein kinase C, action of amyloid beta-protein (A) on protein kinases, identification of factors influencing aggregation and fibrillization of A, interaction of A with membrane lipids and its effect on membrane properties, anti-amyloidogenic, anti-oxidant and anti-apoptotic role of gelsolin, and on oxidative stress, immune response and membrane abnormalities in autism.

Dr. Chauhan′s Interests include reports on calcium traversal across membrane bilayer, the role of phosphoinositides in the activation of protein kinase C, action of amyloid beta protein (A) on protein kinases, identification of factors influencing aggregation and fibrillization of A, interaction of A with membrane lipids and its effect on membrane properties, anti-amyloidogenic, anti-oxidant and antiapoptotic role of gelsolin, and on oxidative stress, immune response and membrane abnormalities in autism.

Fabien Gosselet is researcher at the Bloodbrain barrier BBB laboratory directed by Professor Romeo Cecchelli and located at the faculty of Lens France. His Ph.D. thesis in the biggest cancer hospital in Europe the Gustave Roussy Institute in Villejuif France have consisted to characterize involvement of the Bone Morphogenetic Protein BMP signalling pathway in normal human skin keratinocytes and in tumorigenesis processes Since 2006 he has focused his research activity on the physiology of the endothelial cells and pericytes both composing the BloodBrain Barrier in normal and pathological conditions ie Alzheimer disease. Using an original model consisting to cultivate bovine brain capillary endothelial cells with new born rat glial cells his team studies the transport of A Beta peptides across the BBB and the relationship between brain cholesterol metabolism and Alzheimer disease

Fabien has focused his research activity on the Blood brain barrier physiology in normal and pathological conditions, In vitro and in vivo Blood brain barrier models, Transport of molecules across the Blood brain barrier, Astroglia endothelial interrelations, Cerebral cholesterol metabolism and Blood brain barrier, Biochemistry and signaling pathways at the BBB level, Skin homeostasis and cancerology.

Dr. Cara Westmark is an Associate Scientist at the Waisman Center for Developmental Disabilities at the University of Wisconsin-Madison. Her current research examines the role of genetic and environmental factors on the expression of amyloid precursor protein (APP) and beta-amyloid (A beta) in transgenic mouse models of neurological disorders. She has demonstrated that APP/ A beta levels are altered in Fragile X syndrome and that many FXS phenotypes can be rescued in a mouse model of the disorder by genetically reducing APP/ A beta. These data suggest that therapies studied for the treatment of Alzheimer’s disease (AD) may be beneficial in the treatment of FXS. She has also demonstrated a strong association between APP/ A beta over-expression and lower seizure threshold, which has important implications for the treatment of seizure-related disorders such as AD, FXS and Down syndrome. Her most recent work has demonstrated a strong association between dietary phytoestrogen consumption, elevated A beta and reduced seizure threshold.

Cara current research examines the role of genetic and environmental factors on the expression of amyloid precursor protein (APP) and beta-amyloid (A Beta) in transgenic mouse models of neurological disorders.

Aretouli have participated in several research projects regarding cognitive functioning in normal aging as well as in neurological and psychiatric disorders. She received numerous awards from  publications details. Currently she is investigating predictors of subsequent dementia in persons with MCI neuroanatomical correlates of cognitive functioning and personality traits and cognitive functioning in cognitively healthy adults.

Aretouli Research Interest includes Neuropsychology of degenerative diseases, Mild cognitive impairment and early diagnosis of degenerative diseases, Development of neuropsychological and psychometrical methods-methodological foundations of neuropsychology, Neuropsychological predictors of everyday functioning, Biomarkers of normal and pathological cognitive aging, Neuroanatomical correlates of cognitive functioning and personality.

Chohan is working in the department of neurosurgery at university of New Mexico Hospital and was invited as Guest Editor for a special issue entitled Novel Approaches to Alzheimers Disease Therapeutics for the Journal of Alzheimer Disease 2008 he obtained World Association of Alzheimer Disease Scientists WAADS Award 2005.

Chohans Research Interests include Endovascular, neurobiology of stem cell stimulation, cell based therapies for neurosurgical disorders and CNS tumor stem cells.

Aaron education of Certificate of Science of Clinical Investigation, Johns Hopkins University School of Medicine Baltimore, Maryland, Master of Arts in Decision and Information Sciences, Warrington College of Business Administration University of Florida Gainesville, Florida. Bachelor of Science in Business Administration, 1995 (Graduated with High Honors) Warrington College of Business Administration, University of Florida - Gainesville, Florida. International Business Exchange Program, Bocconi University Milan, Italy.

Aaron research interests includes biomedical informatics, natural language processing, bibliometrics, and scientometrics.

Andrea Tales currently working in the department of Experimental Psychology,
University of Bristol.

Andrea’s Research Interests includes examination of visual attention-related function in Alzheimer’s disease and mild cognitive impairment using psychophysics, EEG and neuro-imaging techniques.

Dr. Hansen Wang is a Research Scientist in the Faculty of Medicine at the University of Toronto. He received his Ph.D. degree from Shandong University, China. Dr. Wang has been studying the neurobiology of human diseases by using genetic and pharmacological approaches. His research mainly focus on the molecular and cellular mechanisms of neurological disorders, such as Fragile X syndrome, Rett syndrome, neuropathic pain and neurodegenerative diseases. He believes that his research may ultimately help identify therapeutic targets for these neurological disorders. Dr. Wang has published and presented frequently for his basic study of neurological disorders. 

Dr. Hansen Wang  research interest include, Neurobiology of diseases, molecular and cellular mechanisms of neurological disorders, such as Fragile X syndrome, Rett syndrome, neuropathic pain and neurodegenerative diseases.

Herukka’s education is as Bachelor in Medicine, Master of Science, Applied biotechnology, Doctor of Philosophy, Neurosciences and she has been as Laboratory technician, Dept of Neuroscience and Neurology, University of Kuopio,Graduate Student, Dept of Neuroscience and Neurology, University of Kuopio and Kuopio University Hospital, Researcher, Dept of Neurology, University of Kuopio, doctor specialising in Neurology, Kuopio University Hospital.

Herukka′s research interests include Biological markers for neurodegenerative diseases, particularly Alzheimer′s disease, Parkinson’s disease and Frontotemporal dementia, Mild cognitive impairment and early Alzheimer′s disease, Imaging of neurodegenerative diasease, Animal models of Alzheimer′s disease, Genetics of neurodenegerative diseases

Theofilou Paraskevi: Ph.D. in Health Psychology (Athens, Panteion University), M.Sc. Social exclusion and minorities (Panteion University), Social Administration - Management of Health Services (Athens, National School of Public Administration), B.Sc. (Psychology) (Panteion University), B.Sc. (Social Work) (Technological Educational Institute of Athens).

Theofilou Paraskevi research interest focuses on, Psychosocial processes, outcomes and quality of life in chronic illness with particular emphasis on chronic kidney disease, dialysis and renal transplantation, Self management interventions for patients with chronic illness.
 

Prof.Dr. Mustafa Nazıroglu has received his Ph.D (Physiology) in Fırat University during the period  of 1992-1996.  Currently, he is working as Head of Department of Biophysics in Suleyman Demirel University (SDU), Medical Faculty. He has successfully completed his administrative responsibilities as Head of department, Head of Congress organization committee, director of Neuroscience Research Center in SDU. As chair of congress, he organized 1st, 2cd and 3th biennale International Congress in Cell Membrane and Oxidative Stress: Focus on Calcium Signaling and TRP channels between 2006-2010, Isparta, Turkey. (www.cmos.org.tr). He is also serving in organization committee of TEMA-14 Congress (2011), Hubei, Chine. He is serving as an editorial member of several reputed journals like ‘Biological Trace Element Research’, ‘Cell Membranes and Free Radical Research, ‘Turkish Journal of Medical Sciences’. He is also review editor in Frontiers in Membrane Physiology and Biophysics. He authored 105 international research articles and 1023 citation in SCI and 5 international book chapters. He is a member of Cell Membranes and Free Radical Society (Head of the society), Turkish Physiological Society and International Brain Research Organization (IBRO). He has honored as ‘Young Investigative Scientist Award (2001), UC-Berkeley, USA, Alexander von Humboldt (AvH) Research fellowship owner (2002-2005), RWTH-Aachen, Germany, Encouragement Award of Scientific and Tech. Res. Council (TUBITAK), Ankara, Turkey (2006), Howard Hudges Medical Institute (USA) support (2009).

Mustafa Nazıroglu’s Research Interest Focuses on Calcium Signaling and TRP channels, Cell Membranes and Free Radical Research, Membrane Physiology and Biophysics.